Introduction: Some glial-neuronal tumors (GNT) (pleomorphic xantho-astrocytoma
| INTRODUCTION
Most primary central nervous system (CNS) neoplasms are gliomas (Dolecek, Propp, Stroup, & Kruchko, 2012) ; CNS neoplasms with a neuronal component are overall rare (Dolecek et al., 2012) .
Circumscribed glial and mixed glial-neuronal tumors (GNT) most often develop in children and young adults and are usually low-grade (grade I or II) according to the 2016 World Health Organization (WHO) classification (Louis et al., 2007) .
BRAF is an oncogene mutated in about half of melanomas (BRAF-V600E mutation in most cases) and in other tumor entities as well (thyroid papillary carcinoma, colorectal carcinoma, hairy cell leukemia, Langerhans cell histiocytosis) (Andrulis, Penzel, Weichert, von Deimling, & Capper, 2012; Garnett & Marais, 2004; Ida et al., 2013; Long et al., 2013; Michaloglou, Vredeveld, Mooi, & Peeper, 2008; Rahman, Salajegheh, Smith, & Lam, 2013; Ritterhouse & Barletta, 2015; Sahm et al., 2012; Schindler et al., 2011) . BRAF rearrangements have also been identified in CNS tumors (Brastianos et al., 2014; Dias-Santagata et al., 2011; Dougherty et al., 2010; KleinschmidtDeMasters, Aisner, Birks, & Foreman, 2013; Koelsche et al., 2013 Koelsche et al., , 2014 . Very recently, the mutation V600E has been reported in 96% of papillary craniopharyngiomas (Brastianos et al., 2014) . The mutation is also detected in about two-thirds of pleomorphic xanthoastrocytomas (PXA), one-third of gangliogliomas (GG) and 20%-25% of dysembryoplastic neuroepithelial tumors (DNT) (Becker et al., 2015; Chappé et al., 2013; Dias-Santagata et al., 2011; Ichimura, Nishikawa, & Matsutani, 2012; Jones et al., 2008; Koelsche et al., 2013; Rodriguez, Lim, Bowers, & Eberhart, 2013; Roth et al., 2015) . Moreover, pilocytic astrocytoma (PA) is characterized by a fusion between the BRAF gene and the locus KIAA1549 (chromosome 7q34) (Faulkner et al., 2015; Jones et al., 2008; Roth et al., 2015) . The fusion causes a constitutional activation of the tyrosine kinase domain of BRAF and a permanent activation of the MAP kinase pathway (MAPK) (Roth et al., 2015) . Of interest, cerebellar PA harbor the BRAF fusion in about 80% of cases while supratentorial (hemispheric) PA present with the fusion in 29% of cases and with the BRAF-V600E mutation in about 5% of cases (Becker et al., 2015; Faulkner et al., 2015; Ichimura et al., 2012; Jones et al., 2008; Rodriguez et al., 2013) . Distinguishing those circumscribed GNT, characterized by an overall favorable prognosis, from diffuse gliomas (diffuse astrocytomas, oligodendrogliomas), that present a dismal prognosis, may be difficult by histopathology alone.
The detection of a BRAF rearrangement has first diagnostic implications as diffuse gliomas do not usually display such an anomaly.
Second, it has therapeutic implications as targeted therapies against mutated BRAF-V600 protein have been recently developed (vemurafenib, dabrafenib) (Hertzman Johansson & Egyhazi Brage, 2014; Lee, Ruland, LeBoeuf, Wen, & Santagata, 2014; Peters et al., 2014; Rutkowski & Blank, 2014) . In routine settings, BRAF-V600E mutation can be identified using Sanger sequencing or allele-specific quantitative polymerase chain reaction (ASQ-PCR) (Ihle et al., 2014 Colomba et al., 2013; Ritterhouse & Barletta, 2015) , and it is sensitive and specific in detecting BRAF-V600E mutation in cutaneous melanomas Colomba et al., 2013; Long et al., 2013) . In contrast, few studies have assessed the reliability of anti-BRAF-V600E immunohistochemistry (IHC) in CNS tumors (Behling et al., 2016; Chappé et al., 2013; Long et al., 2013) .
Some groups have found that BRAF-VE1 IHC was suboptimal in characterizing brain tumor tissue and that MB techniques are required for a reliable clinical assessment. The aim of this study was to assess the utility of BRAF-V600E IHC compared to MB on a large series of glial and GNT.
| MATERIALS AND METHODS
One hundred and forty formalin-fixed paraffin-embedded samples (Louis et al., 2007) . The entire cohort is described in Table 1. For 131 of 140 patients, tumor material from the initial surgery (biopsy or resection) was available.
For nine patients (cases no. 11, 14, 27, 41, 68, 114, 133, and 140; see Table 1 ), the initial sample was not available (exhausted material, surgery at an outside institution), and only the sample obtained at recurrence was reviewed. The protocol and procedures employed were reviewed and approved by the appropriate institutional review committee. The patients were first treated in the Department of Neurosurgery of Angers University Hospital and those who required adjuvant treatment were followed in the pediatric Oncology 
| Immunohistochemical study
Anti-BRAF-V600E IHC (mouse monoclonal antibody, VE1 clone, 
| Detection of BRAF-V600E mutation by molecular biology
Detection of BRAF-V600E mutation was performed by MB on 53 samples (51 initial tumors and two recurrences) in the Department of Genetics and Biochemistry of Angers University Hospital (DPM).
Contributing results were obtained only in 47 of 53 samples.
Briefly, five 10 μm-thick slides were used for DNA extraction. DNA was extracted and purified using the Nucleospin FFPE DNA kit 
| Statistical analysis

| RESULTS
| Clinical and radiological data
One hundred and forty patients were included. The mean age at initial diagnosis was 16.2 years (standard deviation 14 years, range 7 months to 74 years). There were 68 males and 72 females (sex ratio M/F: 0.94). The tumor was located in the cerebellum in 32 cases, in the opto-chiasmatic region in 23 cases, in the cerebral hemispheres in 60 cases, in the basal ganglia in 11 cases, in the brainstem in six cases, in the region of the third ventricle in four cases, in the spinal cord in four cases, and in the pineal region in one case. The entire cohort is described in Table 1 .
| Histopathology
The histopathological diagnosis for the 140 patients was as follows:
PA (58 cases), PMA (two cases), GG/GC (50 cases), AGG (two cases), DNT (seven cases), PXA (six cases), APXA (three cases), astroblastoma (one case), DIG (one case), and PGNT (one case) ( T A B L E 1 (Continued)
were also included (hereafter referred to as LGGNT). Representative microscopic features are shown in Figure 1 .
| Immunohistochemical study
Anti-BRAF-V600E IHC was performed on all samples ( Tables 1 and 2 
| Molecular biology
Fifty-three cases were tested by MB techniques (26 GG, 2 AGG, 14 PA, 4 PXA, 2 APXA, 4 DNT, and one LGGNT). Fifty-two cases were analyzed by ASQ-PCR of whom 37 were also tested by Sanger se- (Table 4) .
Furthermore, in another eight cases, the mutation was detected by IHC and ASQ-PCR, but not by Sanger sequencing. In those eight cases, the frequency of the mutated allele, estimated semiquantitatively by ASQ-PCR, was ≤20%, which corresponds to the detection threshold of the Sanger method (Monzon et al., 2009 ). In our study, we could not reliably assess IHC sensitivity and specificity because we first selected for sequencing the cases displaying weak or equivocal immunostaining. Because of the limited amount of material in many cases, we first tested the tumors with ambiguous or restricted staining for which IHC could not reliably predict BRAF mutation. This selection bias may have artificially lowered the specificity of the IHC test (specificity of 81.5%
and sensitivity of 95% compared to the gold standard (i.e., MB techniques). To determine those values, equivocal cases were considered as negative because a true immunostaining could not be ascertained). 
LGGNT 1 (11%) 7 (78%) 1 (11%) 9 IHC, immunohistochemistry; AB, astroblastoma; PA, pilocytic astrocytoma; PMA, pilomyxoid astrocytoma; DNT, dysembryoplastic neuroepithelial tumor; GG, ganglioglioma; AGG, anaplastic ganglioglioma; PGNT, papillary glioneuronal tumor; PXA, pleomorphic xantho-astrocytoma; APXA, anaplastic pleomorphic xantho-astrocytoma; DIG, desmoplastic infantile ganglioglioma; PGNT, papillary glioneuronal tumor;
LGGNT, low-grade glioneuronal tumor (with varying features). shown that anti-BRAF-V600E IHC had a sensitivity and specificity over 95% in cutaneous melanoma Colomba et al., 2013; Long et al., 2013; Ritterhouse & Barletta, 2015) . In colon and thyroid cancers, IHC also proved consistent (Bösmüller et al., 2013; He, Zhao, Zhang, & Gong, 2014; Ritterhouse & Barletta, 2015) , but its reliability remains to be assessed in large series of primary CNS tumors. We studied BRAF-V600E expression in 140 glial and GNT.
T A B L E 2 Results of anti-BRAF immunohistochemistry according to histopathology T A B L E 3 Comparison between IHC and MB (Sanger sequencing and/or Q-PCR) results for BRAF-V600E mutation
Immunoreactivity with BRAF-VE1 antibody was detected in 61.5% of GG/GC/AGG, 33% of PXA/APXA, 6.6% of PA/PMA, and in no DNT.
Sanger sequencing and/or ASQ-PCR could be performed in 47 cases.
For many specimens, the amount of (FFPE) material available was not sufficient to allow for MB analysis. This fact underlines the key role of IHC in detecting biomarker expression in routine practice. One caveat of our study is that we first selected for sequencing the cases with ambiguous or restricted (few ganglion cells only) staining for which IHC could not reliably predict BRAF mutation. So, no firm conclusion can be drawn from the sensitivity and specificity values in our study.
However, the results of BRAF IHC were very good although inferior to those obtained in melanomas (Colomba et al., 2013; Long et al., 2013) .
We studied few cases of PXA (nine cases) and DNT (seven cases);
this may explain why the frequencies of BRAF-V600E mutation were lower than those reported in the literature (44.5% vs 66% for PXA/ APXA and 0% vs 25% for DNT) (Chappé et al., 2013; Dougherty et al., 2010; Schindler et al., 2011) .
As already mentioned, 38.5% of GG/AGG in our series were immunopositive for BRAF-V600E only in the ganglion cell component.
This observation has been reported in the literature but has not been expanded upon (Koelsche et al., 2013) . However, this finding leads to discuss the detection threshold of MB techniques. GG harbor a variable proportion of ganglion cells, from a few scattered cells to an authentic gangliocytoma (tumor composed entirely of ganglion cells with no glial tumor component) (Louis et al., 2007) . The glial component is most often predominant in GG. In our study, Sanger sequencing did not detect BRAF mutation in 10 cases of GG/AGG that were immunopositive for BRAF. In three of those 10 cases, the immunostaining was detected only in a few ganglion cells but with a significant intensity. In 7 of 10 cases (including two of the three cases with rare immunopositive ganglion cells), the mutation was detected by ASQ-PCR (Table 4) antibody detects only the BRAF-V600E variant even though cross reactivity with non pV600E mutations has been described (e.g., V600K, V600R) (Ihle et al., 2014) . The absence of immunostaining does not rule out another V600 mutation (Ritterhouse & Barletta, 2015) . This is also true for ASQ-PCR, which is designed to detect BRAF-V600E mutant. Only Sanger sequencing can detect the different variants (but with a lower sensitivity compared to ASQ-PCR). Of note, we did not identify BRAF mutation other than the V600E variant. Patients with mutation other than BRAF-V600E are eligible to targeted therapies such as vemurafenib or dabrafenib (Lee et al., 2014; Sosman et al., 2012) . Because of the therapeutic implications, the relevance of detecting BRAF mutation is already expanding to other types of CNS tumors, therefore requiring robust detection techniques. It would be interesting to evaluate newer MB techniques in GNT such as nextgeneration sequencing or pyrosequencing, which is fast, more sensitive and has a better yield compared to Sanger sequencing (Colomba et al., 2013) . Those techniques detect all BRAF mutations but are still expensive and not widely available.
If the presence of BRAF-V600E mutation is a diagnostic clue to a circumscribed low-grade glial or glial-neuronal tumor, this mutation is not specific of GNT; it has been reported in rare cases of low-grade diffuse gliomas in children and in 10% of GB, especially in the epithelioïd variant (which also expresses CD34 more often) (Brastianos et al., 2014; Ichimura et al., 2012; KleinschmidtDeMasters, Aisner, & Foreman, 2015; Kleinschmidt-DeMasters et al., 2013) . The detection of the mutation can still help to distinguish a GG from the cortical infiltration of a diffuse glioma or a GG from an astrocytoma especially in the cerebellum, where PA rarely exhibits BRAF-V600E mutation (but instead the BRAF-KIAA1549 fusion in 80% of cases).
As expected, the percentage of BRAF-V600E mutant PA in our series was low (6.6%), which is comparable to the results obtained in other studies (Chappé et al., 2013; Schindler et al., 2011) . It is interesting to note that the four mutant PA in our cohort were all of supratentorial location (basal ganglia, third ventricle, and optic pathways).
However, extra-cerebellar BRAF-V600E mutant PA remains rare (Roth et al., 2015) leading to wonder whether it is a distinct entity or actually GG whose neuronal component was not sampled.
| CONCLUSION
The detection of BRAF-V600E mutation represents a diagnostic aid in glial and GNT. Targeted therapies against BRAF-V600 mutant proteins have shown promising results. In this context, anti-BRAF-V600E IHC plays a key role in clinical practice, especially as it is a fast, inexpensive, and easily accessed technique. In GG, the presence of the mutation in only scattered neuronal cells reduced the sensitivity of Sanger sequencing. However, ASQ-PCR was able to detect the mutation in few tumor cells. Thus, while waiting for the assessment of newer MB techniques, we should order IHC in addition to ASQ-PCR, which should be preferred to Sanger sequencing in glioneuronal tumors.
